Clinical Trials Browser

ruxolitinib × Head & Neck × Clear all

NCT03153982 2024-10-30

Ruxolitinib in Operable Head and Neck Cancer

Phase 2 Terminated

16 enrolled 9 charts

Squamous Cell Carcinoma of Head and Neck

NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

Phase EARLY_PHASE1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms